Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on May 2, 2003, to disclose a trading plan established by its Chairman and CEO, Joshua S. Boger. This plan, arranged with Goldman, Sachs & Co., outlines the sale of up to 470,000 shares of VRTX stock, which are issuable upon the exercise of stock options held by Dr. Boger. Investors should note that the sales are not immediate. They are scheduled to commence no earlier than 90 days following the plan's adoption, with specific intervals between August 5, 2003, and March 9, 2004. This information is primarily a disclosure of insider trading activity under a structured plan, designed to manage the sale of a significant number of shares over a defined period.
Key Highlights
- 1CEO Joshua S. Boger has entered into a trading plan to sell up to 470,000 shares of VRTX stock.
- 2The shares to be sold are issuable upon the exercise of stock options held by Dr. Boger.
- 3The plan was established with Goldman, Sachs & Co.
- 4Sales are subject to a limit order.
- 5The earliest sales can begin is 90 days after the plan's adoption.
- 6Sales are scheduled to occur at specified intervals between August 5, 2003, and March 9, 2004.